

### 3.3 – CARRYOVER BALANCES

#### Introduction

BsUFA user fees collected, appropriated, and not obligated at the end of a fiscal year remain available to FDA in future fiscal years. These funds are referred to as carryover balances. The operations in FY 2016 resulted in a net increase of the carryover balance of \$13,697,038—from \$38,864,573 to \$52,561,611.

Table 3 reflects the amount of fees collected net of any refunds or other adjustments that occurred during each fiscal year for all cohort years combined, and the amount obligated during the fiscal year. The numbers do not include any accounts receivable. Therefore the numbers for FY 2015 and FY 2016 may differ from the numbers which reflect the total net collections for the cohort years only, as shown in Table 1, section 3.1 – User Fee Collections.

Obligations in Table 3 include any recoveries and deobligations from prior years, which may cause differences from Tables 2 and 6. In FY 2016, FDA did not recover any prior-year BsUFA deobligations.

#### Data

Table 3 captures FDA's carryover balances at the beginning of each fiscal year from the first year of BsUFA implementation.

**TABLE 3: BIOSIMILAR BIOLOGICAL PRODUCT USER FEE COLLECTIONS, OBLIGATIONS, AND CARRYOVER BALANCES BY FISCAL YEAR**

Program	Fiscal Years	Beginning Carryover	Net Collection	Obligations	Year-End Carryover
BsUFA	2013	\$0	\$6,464,085	\$0	\$6,464,085
	2014	\$6,464,085	\$14,141,179	\$2,317,402	\$18,287,862
	2015	\$18,287,862	\$22,843,508	\$2,266,797	\$38,864,573
	2016	\$38,864,573	\$26,913,052	\$13,216,014	\$52,561,611

Numbers have been rounded to the nearest dollar.